# Organogenesis Holdings Inc.: overview

ORGO · Nasdaq · CIK 1661181 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/orgo.md) · [Financials](/companies/orgo/financials.md) · [Filings](/companies/orgo/filings.md) · [Insiders](/companies/orgo/insiders.md)

Latest reported revenue: [$43.8m](/filings/0001193125-26-338049.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-338049).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [115](/filings/0001193125-25-269697.md) | [127 d](/filings/0001193125-26-076730.md) | [86.7](/filings/0001661181-26-000008.md) | [101](/filings/0001193125-26-338049.md) | [151](/filings/0001193125-25-269697.md) | [226 d](/filings/0001193125-26-076730.md) | [37.2](/filings/0001661181-26-000008.md) | [43.8](/filings/0001193125-26-338049.md) |
| Gross margin | % | [76.7%](/filings/0000950170-24-125431.md) | [75.5% d](/filings/0000950170-25-029137.md) | [72.6%](/filings/0000950170-25-066962.md) | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [5.4%](/filings/0001193125-25-269697.md) | [8.1% d](/filings/0001193125-26-076730.md) | [(30.9%)](/filings/0001661181-26-000008.md) | [(12.5%)](/filings/0001193125-26-338049.md) | [13.7%](/filings/0001193125-25-269697.md) | [28.1% d](/filings/0001193125-26-076730.md) | [(185.1%)](/filings/0001661181-26-000008.md) | [(116.5%)](/filings/0001193125-26-338049.md) |
| Net margin | % | [10.7%](/filings/0001193125-25-269697.md) | [6.1% d](/filings/0001193125-26-076730.md) | [(21.7%)](/filings/0001661181-26-000008.md) | [(9.3%)](/filings/0001193125-26-338049.md) | [14.3%](/filings/0001193125-25-269697.md) | [19.4% d](/filings/0001193125-26-076730.md) | [(142.8%)](/filings/0001661181-26-000008.md) | [(220.0%)](/filings/0001193125-26-338049.md) |
| Diluted EPS | $ per share | [0.09](/filings/0001193125-25-269697.md) | not reported | [(0.17)](/filings/0001661181-26-000008.md) | [(0.10)](/filings/0001193125-26-338049.md) | [0.11](/filings/0001193125-25-269697.md) | not reported | [(0.44)](/filings/0001661181-26-000008.md) | [(0.77)](/filings/0001193125-26-338049.md) |
| Free cash flow | $m | [6.1 d](/filings/0001193125-25-269697.md) | [7.6 d](/filings/0001193125-26-076730.md) | [(23.6)](/filings/0001661181-26-000008.md) | [(36.5) d](/filings/0001193125-26-338049.md) | [0.8 d](/filings/0001193125-25-269697.md) | [34.8 d](/filings/0001193125-26-076730.md) | [18.0](/filings/0001661181-26-000008.md) | [(32.8) d](/filings/0001193125-26-338049.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [467](/filings/0000950170-24-023150.md) | [451](/filings/0000950170-25-029137.md) | [433](/filings/0001193125-26-076730.md) | [482](/filings/0001193125-26-076730.md) | [564](/filings/0001193125-26-076730.md) |
| Gross margin | % | [75.6%](/filings/0000950170-24-023150.md) | [76.7%](/filings/0000950170-25-029137.md) | [75.4%](/filings/0000950170-25-029137.md) | [76.0%](/filings/0000950170-25-029137.md) | not reported |
| Operating margin | % | [15.5%](/filings/0000950170-24-023150.md) | [4.9%](/filings/0000950170-25-029137.md) | [2.9%](/filings/0001193125-26-076730.md) | [(0.3%)](/filings/0001193125-26-076730.md) | [7.9%](/filings/0001193125-26-076730.md) |
| Net margin | % | [20.2%](/filings/0000950170-24-023150.md) | [3.4%](/filings/0000950170-25-029137.md) | [1.1%](/filings/0001193125-26-076730.md) | [0.2%](/filings/0001193125-26-076730.md) | [6.6%](/filings/0001193125-26-076730.md) |
| Diluted EPS | $ per share | [0.70](/filings/0000950170-24-023150.md) | [0.12](/filings/0000950170-25-029137.md) | [0.04](/filings/0001193125-26-076730.md) | [(0.01)](/filings/0001193125-26-076730.md) | [0.15](/filings/0001193125-26-076730.md) |
| Free cash flow | $m | [30.8](/filings/0000950170-24-023150.md) | [(9.0)](/filings/0000950170-25-029137.md) | [6.6](/filings/0001193125-26-076730.md) | [4.2](/filings/0001193125-26-076730.md) | [(24.5)](/filings/0001193125-26-076730.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/orgo/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $28.5m | 11,721,609 |  | Added +104,814 |
| [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $24.6m | 10,140,951 |  | Added +55,000 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $17.6m | 7,249,528 |  | Added +2,349,777 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $7.4m | 3,050,297 |  | Added +159,291 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $7.3m | 3,011,753 |  | Added +2,130,036 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.1m | 2,905,919 |  | Added +5,103 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $7.0m | 2,888,313 |  | Added +590,339 |
| [Assenagon Asset Management S.A.](/funds/1546007.md) | 2026-06-30 | $4.8m | 1,967,952 |  | Unchanged |
| [Assenagon Asset Management S.A.](/funds/1546007.md) | 2026-06-30 | $4.8m | 1,967,952 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.7m | 1,935,554 |  | Added +151,590 |

## Recent filings

[All 670 filings](/companies/orgo/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 16:45 ET | [8-K](/filings/0001193125-26-338321.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-338321 |
| 2026-08-06 | 16:15 ET | [10-Q](/filings/0001193125-26-338049.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338049 |
| 2026-08-06 | 16:11 ET | [8-K](/filings/0001193125-26-338022.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338022 |
| 2026-06-16 | 16:32 ET | [8-K](/filings/0001193125-26-272710.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-272710 |
| 2026-05-07 | 16:16 ET | [10-Q](/filings/0001661181-26-000008.md) | Quarterly report, period 2026-03-31 | 0001661181-26-000008 |
| 2026-05-07 | 16:11 ET | [8-K](/filings/0001661181-26-000007.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001661181-26-000007 |
| 2026-04-30 | 16:17 ET | [DEF 14A](/filings/0001193125-26-197357.md) | Proxy statement, period 2026-06-15 | 0001193125-26-197357 |
| 2026-02-26 | 16:15 ET | [10-K](/filings/0001193125-26-076730.md) | Annual report, period 2025-12-31 | 0001193125-26-076730 |
| 2026-02-26 | 16:09 ET | [8-K](/filings/0001193125-26-076595.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-076595 |
| 2026-02-23 | 17:02 ET | [8-K](/filings/0001193125-26-064270.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-064270 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076730.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/f84eb628-3694-436c-94b1-f5bc7434c282)

## About the filer

- CIK: 1661181
- Tickers: ORGO
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.